https://www.selleckchem.com/products/amg510.html
For advanced non-small cell lung cancer anti-PD-1 treatment has become standard care in first and second line treatment in recent years. Because many of the clinical trials with anti-PD-1 drugs have only recently been completed, long term follow up data of patients treated with these agents is scarce, even more so of patients treated in real life clinical care. We present long term follow up of patients treated with nivolumab. Two hundred forty-eight patients with pre-treated, advanced NSCLC who received nivolumab between August 2015 and
Aimer
Commentaire
Partagez
